Resources

A Phase 1b Food Effect Study of the First-in-Class, Oral, Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas

• PDF (2.68 MB)

A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (selinexor) in Patients with Heavily Pretreated Non-Hodgkin’s Lymphoma (NHL)

• PDF (1.70 MB)

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

• External Link

Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma.

• External Link

Clinical Translation of Nuclear Export Inhibitors in Cancer

• External Link

Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy

• PDF (2.42 MB)

Mitochondrial priming of new targeted agents in acute myeloid leukemia

• PDF (1.19 MB)

Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer

• PDF (1.27 MB)

Novel activity of selective inhibitors of nuclear export in epithelial-to-mesenchymal transition models

• PDF (575.79 KB)

Novel small molecule pak4 allosteric modulators with activity against pancreatic cancer

• PDF (1.32 MB)